Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress

Lipids

Volumn 46, Issue 4, 2011, Pages 341-348

  Kostapanos, Michael S ^a   Spyrou, Athanasia T ^a   Tellis, Constantinos C ^b   Gazi, Irene F ^a   Tselepis, Alexandros D ^b   Elisaf, Moses ^a   Liberopoulos, Evangelos N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

8 Isoprostanes; Ezetimibe; Hypercholesterolemia; Oxidative stress; Oxidized LDL; Pleiotropic actions; Reactive oxygen metabolites

Indexed keywords

APOLIPOPROTEIN; EZETIMIBE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OXIDATIVE STRESS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; DINOPROST; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 79956031420     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3539-z     Document Type: Article

References (32)

1. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report (2002) Circulation 106:3143-3421
2. Ong HT (2005) The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98:599-614
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
4. Kostapanos MS, Milionis HJ, Elisaf MS (2008) An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13:157-174
5. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA (2005) The target of ezetimibe is Niemann-Pick c1-like 1 (npc1l1). Proc Natl Acad Sci USA 102:8132-8137 (Pubitemid 40800055)
6. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, Monkman D, Patel V, Pittard J, Schachter M (2005) The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 21:959-969 (Pubitemid 40896244)
7. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR (2008) Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 101:490-496 (Pubitemid 351199443)
8. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358:1431-1443 (Pubitemid 351482735)
9. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ (2008) Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (stop atherosclerosis in native diabetics study) trial. J Am Coll Cardiol 52:2198-2205
10. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ (2010) The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55:2721-2726
11. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343-1356
12. Kalogirou M, Tsimihodimos V, Elisaf M (2010) Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 633:62-70
13. Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29-38 (Pubitemid 40054251)
14. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL (2004) Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109:IV6-IV19
15. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR (2006) Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 47:2575-2580 (Pubitemid 44936118)
16. Yamaoka-Tojo M, Tojo T, Kosugi R, Hatakeyama Y, Yoshida Y, Machida Y, Aoyama N, Masuda T, Izumi T (2009) Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis 8:41
17. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J (2008) Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 65:637-645 (Pubitemid 351535082)
18. Harris WS, Held SJ, Dujovne CA (1995) Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk 2:359-365
19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239 (Pubitemid 38924592)
20. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M (2006) Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther 11:256-261 (Pubitemid 44936239)
21. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663-669 (Pubitemid 26388165)
22. Tsouli SG, Kiortsis DN, Lourida ES, Xydis V, Tsironis LD, Argyropoulou MI, Elisaf M, Tselepis AD (2006) Autoantibody titers against oxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 47:2208-2214 (Pubitemid 44936131)
23. Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A (2001) Bioavailability and antioxidant activity of some food supplements in men and women using the d-ROMs test as a marker of oxidative stress. J Nutr 131:3208-3211 (Pubitemid 33136136)
24. Kaneko K, Taniguchi N, Tanabe Y, Nakano T, Hasui M, Nozu K (2009) Oxidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol 24:869-871
25. Vassalle C (2008) An easy and reliable automated method to estimate oxidative stress in the clinical setting. Methods Mol Biol 477:31-39
26. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD (2007) Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 27:2236-2243 (Pubitemid 350287255)
27. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 24:1919-1929
28. Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162-1167 (Pubitemid 34764868)
29. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848 (Pubitemid 32448777)
30. Turfaner N, Uzun H, Balci H, Ercan MA, Karter YH, Caner M, Sipahioglu F, Genc H (2010) Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med J 103:428-433
31. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC (2004) Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 256:308-315 (Pubitemid 39304342)
32. Bertuglia S, Giusti A (2005) Role of nitric oxide in capillary perfusion and oxygen delivery regulation during systemic hypoxia. Am J Physiol Heart Circ Physiol 288:H525-H531 (Pubitemid 40139634)